FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011861566> ?p ?o ?g. }

• W2011861566 endingPage "1184" @default.
• W2011861566 startingPage "1177" @default.
• W2011861566 abstract "Nonsteroidal anti-inflammatory drugs and sulfinpyrazone compete dose-dependently with arachidonate for binding to platelet cyclooxygenase. Such a process closely follows systemic plasma drug concentrations and is reversible as a function of drug elimination. Peak inhibition and extent of its reversibility at 24 hr varies consistently with individual pharmacokinetic profile. Inhibition of platelet cyclooxygenase activity by these agents is associated with variable effects on prostaglandin (PG) synthesis in the gastric mucosa and the kidney. Aspirin acetylates platelet cyclooxygenase and permanently inhibits thromboxane (TX) A2 production in a dose-dependent fashion when single doses of 0.1 to 2.0 mg/kg are given. Acetylation of the enzyme by low-dose aspirin is cumulative on repeated dosing. The fractional dose of aspirin necessary to achieve a given level of acetylation by virtue of cumulative effects approximately equals the fractional daily platelet turnover. Serum TXB2 measurements obtained during long-term dosing with 0.11, 0.22, and 0.44 mg/kg aspirin in four healthy subjects could be fitted by a theoretical model assuming identical acetylation of platelet (irreversible) and megakaryocyte (reversible) cyclooxygenase. For a given dose within this range, both the rate at which cumulative acetylation occurs and its maximal extent largely depend upon the rate of platelet turnover. Continuous administration of low-dose aspirin (20 to 40 mg/day) has no statistically significant effect on urinary excretion of either 6-keto-PGF1 alpha or 2,3-dinor-6-keto-PGF1 alpha, i.e., indexes of renal and extrarenal PGI2 biosynthesis in vivo. Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials." @default.
• W2011861566 created "2016-06-24" @default.
• W2011861566 creator A5004595193 @default.
• W2011861566 creator A5010013725 @default.
• W2011861566 creator A5023734530 @default.
• W2011861566 creator A5037319421 @default.
• W2011861566 creator A5037962146 @default.
• W2011861566 creator A5047213840 @default.
• W2011861566 creator A5071758568 @default.
• W2011861566 creator A5083907352 @default.
• W2011861566 date "1985-12-01" @default.
• W2011861566 modified "2023-10-16" @default.
• W2011861566 title "Clinical pharmacology of platelet cyclooxygenase inhibition." @default.
• W2011861566 cites W1419652914 @default.
• W2011861566 cites W1492859240 @default.
• W2011861566 cites W1967999463 @default.
• W2011861566 cites W1971804850 @default.
• W2011861566 cites W1980795734 @default.
• W2011861566 cites W1983759759 @default.
• W2011861566 cites W1984195800 @default.
• W2011861566 cites W2003363140 @default.
• W2011861566 cites W2003525499 @default.
• W2011861566 cites W2010786943 @default.
• W2011861566 cites W2014644245 @default.
• W2011861566 cites W2018522919 @default.
• W2011861566 cites W2018974521 @default.
• W2011861566 cites W2032466310 @default.
• W2011861566 cites W2044880765 @default.
• W2011861566 cites W2050677820 @default.
• W2011861566 cites W2055075682 @default.
• W2011861566 cites W2070158761 @default.
• W2011861566 cites W2080750144 @default.
• W2011861566 cites W2087537112 @default.
• W2011861566 cites W2090672375 @default.
• W2011861566 cites W2091813106 @default.
• W2011861566 cites W2091873526 @default.
• W2011861566 cites W2092011140 @default.
• W2011861566 cites W2100858861 @default.
• W2011861566 cites W2119064142 @default.
• W2011861566 cites W2125389594 @default.
• W2011861566 cites W2162637702 @default.
• W2011861566 cites W2316102942 @default.
• W2011861566 cites W2316166446 @default.
• W2011861566 cites W2317069681 @default.
• W2011861566 cites W2323719464 @default.
• W2011861566 cites W2325212973 @default.
• W2011861566 cites W2399236170 @default.
• W2011861566 cites W2410464431 @default.
• W2011861566 cites W3169105340 @default.
• W2011861566 cites W76482949 @default.
• W2011861566 cites W85630666 @default.
• W2011861566 doi "https://doi.org/10.1161/01.cir.72.6.1177" @default.
• W2011861566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3933848" @default.
• W2011861566 hasPublicationYear "1985" @default.
• W2011861566 type Work @default.
• W2011861566 sameAs 2011861566 @default.
• W2011861566 citedByCount "392" @default.
• W2011861566 countsByYear W20118615662012 @default.
• W2011861566 countsByYear W20118615662013 @default.
• W2011861566 countsByYear W20118615662014 @default.
• W2011861566 countsByYear W20118615662015 @default.
• W2011861566 countsByYear W20118615662016 @default.
• W2011861566 countsByYear W20118615662017 @default.
• W2011861566 countsByYear W20118615662018 @default.
• W2011861566 countsByYear W20118615662019 @default.
• W2011861566 countsByYear W20118615662020 @default.
• W2011861566 countsByYear W20118615662021 @default.
• W2011861566 countsByYear W20118615662022 @default.
• W2011861566 countsByYear W20118615662023 @default.
• W2011861566 crossrefType "journal-article" @default.
• W2011861566 hasAuthorship W2011861566A5004595193 @default.
• W2011861566 hasAuthorship W2011861566A5010013725 @default.
• W2011861566 hasAuthorship W2011861566A5023734530 @default.
• W2011861566 hasAuthorship W2011861566A5037319421 @default.
• W2011861566 hasAuthorship W2011861566A5037962146 @default.
• W2011861566 hasAuthorship W2011861566A5047213840 @default.
• W2011861566 hasAuthorship W2011861566A5071758568 @default.
• W2011861566 hasAuthorship W2011861566A5083907352 @default.
• W2011861566 hasBestOaLocation W20118615661 @default.
• W2011861566 hasConcept C112705442 @default.
• W2011861566 hasConcept C126322002 @default.
• W2011861566 hasConcept C134018914 @default.
• W2011861566 hasConcept C150903083 @default.
• W2011861566 hasConcept C181199279 @default.
• W2011861566 hasConcept C185592680 @default.
• W2011861566 hasConcept C207001950 @default.
• W2011861566 hasConcept C2776785769 @default.
• W2011861566 hasConcept C2777628954 @default.
• W2011861566 hasConcept C2777738910 @default.
• W2011861566 hasConcept C2779689624 @default.
• W2011861566 hasConcept C2781080829 @default.
• W2011861566 hasConcept C55493867 @default.
• W2011861566 hasConcept C71924100 @default.
• W2011861566 hasConcept C86803240 @default.
• W2011861566 hasConcept C89560881 @default.
• W2011861566 hasConcept C98274493 @default.
• W2011861566 hasConceptScore W2011861566C112705442 @default.
• W2011861566 hasConceptScore W2011861566C126322002 @default.

• next